Scarica l'app Stockscreener
90.89
1.29%
1.19
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$89.70
Aprire:
$89.97
Volume 24 ore:
1.58M
Relative Volume:
0.21
Capitalizzazione di mercato:
$116.40B
Reddito:
$33.54B
Utile/perdita netta:
$4.66B
Rapporto P/E:
25.11
EPS:
3.62
Flusso di cassa netto:
$5.19B
1 W Prestazione:
+1.84%
1M Prestazione:
+5.24%
6M Prestazione:
+3.44%
1 anno Prestazione:
+14.58%
Intervallo 1D:
$89.81
$91.15
Intervallo di 1 settimana:
$88.35
$91.15
Portata 52W:
$78.32
$96.25
Medtronic Plc Stock (MDT) Company Profile
Nome
Medtronic Plc
Settore
Industria
Telefono
01135314381700
Indirizzo
BUILDING TWO PARKMORE BUSINESS PARK WEST, GALWAY
Confronta MDT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MDT
Medtronic Plc
|
90.85 | 114.97B | 33.54B | 4.66B | 5.19B | 3.62 |
|
ABT
Abbott Laboratories
|
124.81 | 229.71B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.62 | 154.35B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
392.32 | 149.60B | 23.22B | 2.86B | 3.58B | 7.40 |
|
EW
Edwards Lifesciences Corp
|
76.34 | 45.92B | 5.54B | 4.18B | 623.10M | 7.00 |
Medtronic Plc Stock (MDT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-30 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-06-16 | Iniziato | Leerink Partners | Outperform |
| 2025-03-04 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-10-10 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-08-21 | Reiterato | Oppenheimer | Perform |
| 2024-08-15 | Aggiornamento | UBS | Sell → Neutral |
| 2024-08-14 | Downgrade | Stifel | Buy → Hold |
| 2024-05-30 | Iniziato | Goldman | Sell |
| 2023-07-19 | Iniziato | Robert W. Baird | Neutral |
| 2023-06-30 | Iniziato | CL King | Buy |
| 2023-05-30 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-04-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-29 | Downgrade | UBS | Buy → Sell |
| 2023-01-09 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-11-23 | Downgrade | Citigroup | Buy → Neutral |
| 2022-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-11-16 | Downgrade | Deutsche Bank | Buy → Hold |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-13 | Iniziato | Mizuho | Buy |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-08-24 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-07-06 | Iniziato | Wolfe Research | Underperform |
| 2022-06-01 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-05-27 | Downgrade | Needham | Buy → Hold |
| 2022-04-13 | Downgrade | Truist | Buy → Hold |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-01-10 | Downgrade | BTIG Research | Buy → Neutral |
| 2022-01-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-12-17 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-12-16 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2021-12-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-06-10 | Ripresa | Cowen | Outperform |
| 2021-05-25 | Iniziato | Barclays | Equal Weight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2020-12-15 | Aggiornamento | Goldman | Sell → Neutral |
| 2020-12-15 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-10-08 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2020-10-08 | Aggiornamento | Stifel | Hold → Buy |
| 2020-09-11 | Iniziato | Wolfe Research | Peer Perform |
| 2020-05-14 | Downgrade | DZ Bank | Buy → Hold |
| 2020-03-30 | Downgrade | Needham | Strong Buy → Buy |
| 2020-03-25 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2020-02-13 | Iniziato | Goldman | Sell |
| 2020-01-08 | Iniziato | SunTrust | Buy |
| 2020-01-02 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-06-05 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2019-02-04 | Reiterato | Needham | Strong Buy |
| 2019-01-03 | Iniziato | Deutsche Bank | Buy |
| 2019-01-02 | Downgrade | Citigroup | Buy → Neutral |
| 2018-12-19 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-11-28 | Iniziato | UBS | Buy |
| 2018-10-16 | Iniziato | Barclays | Overweight |
| 2018-08-27 | Reiterato | Argus | Buy |
Mostra tutto
Medtronic Plc Borsa (MDT) Ultime notizie
What analysts say about Medtronic plc stockTurbocharged investment results - jammulinksnews.com
What drives Medtronic plc stock priceRobust investment performance - jammulinksnews.com
Medtronic plc Stock Analysis and ForecastTremendous portfolio expansion - jammulinksnews.com
Medtronic gets EU nod for MiniMed 780G System - MSN
Published on: 2025-07-22 10:22:55 - jammulinksnews.com
Medtronic (MDT): A Shariah-Compliant Powerhouse in the Evolving Medical Device Sector - AInvest
Medtronic’s (MDT) Role in Medical Devices: A Unique Fit for Halal Portfolios - Insider Monkey
Medtronic MiniMed 780G wins CE mark for type 2 diabetes, young children - MassDevice
Court Nixes Jury Award Over Medtronic's Heart Valve Infringement ClaimMedtronic (NYSE:MDT) - Benzinga
Medtronic gets EU nod for MiniMed 780G System (MDT:NYSE) - Seeking Alpha
Medtronic (MDT) Expands MiniMed 780G System Indications with Eur - GuruFocus
Medtronic expands MiniMed 780G system indications across Europe - Investing.com Australia
Medtronic secures CE Mark for MiniMed™ 780G System for insulin-requiring people with diabetes including expanded indications in children as young as two, during pregnancy, and for type 2 diabetes - Medtronic
10 Magnificent S&P 500 Dividend Stocks Down Over 10% to Buy and Hold Forever - The Motley Fool
Is Medtronic plc a good long term investmentUnprecedented market success - Autocar Professional
Medtronic escapes $106.5M payment in Colibri TAVR patent suit after court overturns jury verdict - MassDevice
Fed. Circ. Frees Medtronic From $125M Patent Judgment - Law360
Medtronic wins appeal to avoid $106.5M patent verdict (MDT:NYSE) - Seeking Alpha
Medtronic wins US appeal to overturn $106.5 mln heart-valve patent verdict - Reuters
Breaking Barriers: Medtronic and Zverev Unite - Il Messaggero
Medtronic’s SWOT analysis: renal denervation, diabetes spin-off to drive stock - Investing.com
Medtronic enrolls first patient in study for Onyx liquid embolic system - MassDevice
Analyst Expectations For Medtronic's Future - Benzinga
Got Their Backs: How Medtronic Brings Spine Surgeries to Kids - Yahoo Finance
Medtronic gets CE mark for robot-driven vessel-sealing device - MedTech Dive
Baird Adjusts Medtronic Price Target to $94 From $92, Maintains Neutral Rating - MarketScreener
Morgan Stanley Adjusts Medtronic Price Target to $107 From $98, Maintains Overweight Rating - MarketScreener
Medtronic : first in the U.S. to offer 400 cm 0.018” peripheral guidewire for transradial access - MarketScreener
Medtronic, Renal Denervation, and the Power of Persistence - Medical Device and Diagnostic industry
Medtronic (MDT) Price Target Raised by Morgan Stanley | MDT Stoc - GuruFocus
Medtronic shaping future of surgery, secures CE Mark for LigaSure™ technology on Hugo™ robotic-assisted surgery system - Medtronic
Medtronic (MDT) Experiences Increased Bearish Options Activity | MDT Stock News - GuruFocus
Prostate Care Market Report 2025-2031 | Medtronic, Johnson & Johnson, Boston Scientific, and Abbott Laboratories Dominate through Product Innovations, Clinical Trials, M&As, and Strategic Partnerships - Yahoo Finance
Medtronic Stock Is Climbing Friday: What's Going On?Medtronic (NYSE:MDT) - Benzinga
Medtronic (MDT) Stock Insights and Investment Tools | MDT Stock News - GuruFocus
Medtronic (MDT) Gains from CMS Proposal on Renal Denervation Coverage | MDT Stock News - GuruFocus
Medtronic Says Centers for Medicare & Medicaid Services Proposes National Coverage for Blood Pressure Treatment Device - MarketScreener
Unusual Options Activity Noticed for Medtronic (MDT) | MDT Stock News - GuruFocus
Medtronic (MDT) Set for Growth with Proposed Coverage for Renal Denervation | MDT Stock News - GuruFocus
Medtronic (MDT) Gains Following Medicare's Review of New Hypertension Technology | MDT Stock News - GuruFocus
William Blair reiterates Market Perform rating on Medtronic stock after CMS proposal - Investing.com
Medtronic, Recor praise new CMS coverage for renal denervation - MassDevice
Medtronic : issues statement on the U.S. Centers for Medicare & Medicaid Services proposed National Coverage Determination for Symplicity Spyral™ renal denervation (RDN) system - MarketScreener
Citi Analyst Boosts Medtronic (MDT) Price Target to $99 | MDT Stock News - GuruFocus
Needham Keeps Hold Rating on Medtronic (MDT) Amid Spin-Off News - MSN
Medtronic (MDT) Gains As Market Dips: What You Should Know - Yahoo Finance
Medtronic names CFO for diabetes spinoff - MedTech Dive
Medtronic announces appointment of MiniMed chief financial officer ahead of intended separation into standalone companyJul 8, 2025 - Medtronic
Why Is Merit Medical Stock Trading Higher On Tuesday?Merit Medical Systems (NASDAQ:MMSI) - Benzinga
Medtronic Names CFO For New Diabetes Company Ahead Of Intended Spin-Off - MSN
First Patient Treated in Medtronic Multi-Organ SPYRAL GEMINI Pilot Study - Diagnostic and Interventional Cardiology
Medtronic Plc Azioni (MDT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.36%
0.24%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):